Provectus Biopharmaceuticals Inc.

354 articles about Provectus Biopharmaceuticals Inc.

• Provectus Biopharmaceuticals Inc. Retains Allison+Partners As New Media Relations Consultant

  6/2/2015

• Provectus Biopharmaceuticals Inc.’ Abstract On Liver Cancer Accepted For Poster Presentation At 6th Asia-Pacific Primary Liver Cancer Expert Meeting

  5/29/2015

• Provectus Biopharmaceuticals Inc.’s Abstract Accepted For Poster Presentation At 5th European Post-Chicago Melanoma / Skin Cancer Meeting

  5/28/2015

• Provectus Biopharmaceuticals Inc. Extends For Additional 60 Days Memorandum Of Understanding With Sinopharm-China State Institute Of Pharmaceutical Industry And Sinopharm A-Think Pharmaceutical Co., Ltd

  5/18/2015

• Provectus Biopharmaceuticals Inc.’ Poster Presentation On PV-10 Clinical Data From Phase 1 Study For Cancers Of The Liver Scheduled For Thursday, July 2, 2015 At 17th World Congress On Gastrointestinal Cancer

  5/15/2015

• Provectus Biopharmaceuticals Inc. Updates Market On Business Developments

  5/8/2015

• Provectus Biopharmaceuticals Inc. Reports First Quarter Financial Results

  5/7/2015

• Provectus Biopharmaceuticals Inc.'s Novel Synthesis Patent Application Allowed By European Patent Office, Patent Issued By Japan

  5/5/2015

• Provectus Biopharmaceuticals Inc.’ Abstract On Liver Cancer Accepted For Poster Presentation At European Society For Medical Oncology’s 17th World Congress On Gastrointestinal Cancer

  4/30/2015

• Provectus Biopharmaceuticals Inc. Will Hold Its Quarterly Business Update Conference Call At 4 PM Eastern, Thursday, May 7, 2015

  4/29/2015

• Provectus Biopharmaceuticals Inc. To Present At Asia Biotech Invest 2015 Conference Wednesday, May 20, 2015, Hong Kong

  4/27/2015

• Provectus Biopharmaceuticals Inc. And Sinopharm Facing MOU Deadline For Partnership

  4/27/2015

• Pfizer And Provectus Biopharmaceuticals Inc. Receive Patent Allowance For Use Of PV-10 In Combination With Systemic Immunotherapy Agents In Treatment Of Cancer

  4/20/2015

• Provectus Biopharmaceuticals Inc. Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial Of PV-10 For Melanoma

  4/16/2015

• Provectus Biopharmaceuticals Inc. To Present At 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, Shanghai, China

  4/8/2015

• Provectus Biopharmaceuticals Inc.’ Data On PV-10 To Be Presented At Hemonc Today Melanoma And Cutaneous Malignancies Annual Meeting

  4/7/2015

• Provectus Biopharmaceuticals Inc. Will Present At The Growth Capital Expo, Las Vegas At 1 Pm PDT On Monday April 13, 2015

  4/2/2015

• Provectus Biopharmaceuticals Inc. Will Present At The 12th Annual BIO Asia International Conference Wednesday, March 25, 2015

  3/20/2015

• Provectus Biopharmaceuticals Inc.’ Amended Protocol Of PV-10 For Phase III Study As Treatment For Melanoma Now Available Online

  3/16/2015

• Provectus Biopharmaceuticals Inc. Updates Market On Business Developments

  3/12/2015